PsyPost Psychedelic Research

September 30, 2026

Eine einzelne MDMA-Dosis verhindert bei genetisch besonders gefährdeten Ratten einen traumabedingten Anstieg des Alkoholkonsums

psypost.org · Sep 30, 2026 · Eric W. Dolan

MDMA Article Clinical Research Safety DE

September 28, 2026

Psychedelics reduce bottom-up brain activity in the default mode network across humans and mice

psypost.org · Sep 28, 2026 · Karina Petrova

LSD Psilocybin Article Clinical +2

September 27, 2026

Exploratory clinical trial finds ayahuasca combined with meaning reconstruction therapy may ease severe bereavement

psypost.org · Sep 27, 2026 · Karina Petrova

Ayahuasca Article Clinical Research Therapy

September 25, 2026

Scientists identify the LSD structural elements that trigger hallucinations and create a promising non-hallucinogenic antipsychotic analogue

psypost.org · Sep 25, 2026 · Eric W. Dolan

LSD Article Clinical Research Safety

September 24, 2026

Psilocybin durably increases sociability in an autism mouse model even when administered under anesthesia

psypost.org · Sep 24, 2026 · Eric W. Dolan

Psilocybin Article Clinical Research Safety

September 23, 2026

First fMRI study of mescaline in awake rats finds reduced cerebellar activity, increased brain connectivity, and frequency-specific sensory filtering

psypost.org · Sep 23, 2026 · Bianca Setionago

Mescaline Article Consciousness Research Safety

September 20, 2026

Psilocybin and escitalopram similarly reduce negative emotional bias in depression, despite different effects on the brain

psypost.org · Sep 20, 2026 · Karina Petrova

Psilocybin Article Clinical Research Therapy

September 10, 2026

Preclinical mouse study finds psilocybin may prevent chemotherapy-induced nerve damage by preserving mitochondrial transport

psypost.org · Sep 10, 2026 · Eric W. Dolan

Psilocybin Article Clinical Research Safety

September 5, 2026

Erste Humanstudie zu Psilocin seit den 1960er-Jahren zeigt ähnliche psychedelische Wirkung und bessere Verträglichkeit als Psilocybin

psypost.org · Sep 5, 2026 · Eric W. Dolan

Psilocybin Article Clinical Research Safety DE

September 3, 2026

Psilocin rapidly increases synapse formation in cultured rat neurons, matching ketamine and lithium in a laboratory comparison

psypost.org · Sep 3, 2026 · Karina Petrova

Psilocybin Ketamine Article Clinical +2

September 2, 2026

Psilocybin combined with psychotherapy reduces cocaine use, while animal findings highlight the need for relapse-prevention support

psypost.org · Sep 2, 2026 · Eric W. Dolan

Psilocybin Ibogaine Article Clinical +2

German students showed small shifts in openness and conscientiousness after first psychedelic use, but causality remains uncertain

psypost.org · Sep 2, 2026 · Bianca Setionago

Article Consciousness Research Safety

September 1, 2026

Eine neue Studie zeigt, wie DMT die kritische Dynamik von Gehirnwellen verändert und dadurch mit der Auflösung des Selbst zusammenhängt

psypost.org · Sep 1, 2026 · Karina Petrova

DMT Article Clinical Consciousness Research

August 31, 2026

Low-dose DOI pretreatment reduces inflammation and sickness-like behavior after immune challenge in male mice

psypost.org · Aug 31, 2026 · Karina Petrova

2C-X Article Clinical Research Safety

August 30, 2026

Positive emotional states, not mystical experiences, may explain symptom relief in MDMA-assisted therapy for PTSD

psypost.org · Aug 30, 2026 · Eric W. Dolan

MDMA Article Clinical Research Therapy

August 27, 2026

Salvinorin A from the hallucinogenic mint Salvia divinorum reduces facial nerve pain in mice through cannabinoid and vanilloid receptors

psypost.org · Aug 27, 2026 · Karina Petrova

Salvia Article Clinical Ethnobotany Research

August 25, 2026

Salvinorin A shows preclinical promise for pain, addiction, and stroke, but side effects and its brief action limit therapeutic potential

psypost.org · Aug 25, 2026 · Bianca Setionago

Salvia Article Clinical Research Safety

August 22, 2026

Psychedelic raves emerge as modern rites of passage, with Israeli attendees reporting complex after-effects

psypost.org · Aug 22, 2026 · Bianca Setionago

LSD MDMA Article Culture +2

August 20, 2026

Meta-analysis finds MDMA raises oxytocin, peaking 150 to 200 minutes after administration and remaining slightly elevated for up to five hours

psypost.org · Aug 20, 2026 · Karina Petrova

MDMA Article Clinical Research Therapy

August 16, 2026

A single psilocybin dose relieved chronic pain and depression-like behaviors in mice by calming hyperactive brain cells

psypost.org · Aug 16, 2026 · Karina Petrova

Psilocybin Article Clinical Research Safety

August 13, 2026

Daily psilocin mucate reduces cortisol and anxiety-like behavior in stressed rats, while weekly dosing shows no significant effect

psypost.org · Aug 13, 2026 · Vladimir Hedrih

Psilocybin Article Clinical Research Safety

August 12, 2026

Engineered psychedelic analog in mice retains antidepressant-like and anti-inflammatory effects while avoiding the severe gastrointestinal distress seen with ibogaine

psypost.org · Aug 12, 2026 · Eric W. Dolan

Ibogaine Article Research Safety Therapy

August 10, 2026

5-MeO-DMT zeigt in einer ersten klinischen Studie Potenzial gegen postpartale Depression mit rascher Wirkung und anhaltender Symptomverbesserung

psypost.org · Aug 10, 2026 · Karina Petrova

5-MeO-DMT Article Clinical Research Therapy DE

August 9, 2026

Psilocybin combined with psychotherapy shows early promise for anorexia nervosa, with pilot data indicating symptom relief, safety, and high treatment acceptability

psypost.org · Aug 9, 2026 · Eric W. Dolan

Psilocybin Article Clinical Research Therapy

August 7, 2026

Psilocybin therapy for PTSD relies heavily on silence, with patients speaking less during dosing than in preparation or integration sessions

psypost.org · Aug 7, 2026 · Eric W. Dolan

Psilocybin Clinical Research Therapy